Frontlight ResearchEarly access
Taking peoplePhase 4
ASPIRING
Key facts
- Who runs it
- University Of Edinburgh
- Where
- Belgium and Netherlands28 sites in 2 countriesChoose a country to see its sites
- Trial code
- EU 2024-516188-10-00
- ISRCTN16705062
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 596 people, planned
- Started
- 7 Oct 2025
- Expected to end
- 1 Aug 2030
- Type of study
- Interventional
- Record updated
- 7 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Stroke due to intracerebral haemorrhage (ICH), diagnosed by brain imaging, with symptom onset at least 24 hours before randomisation
- Age ≥18 years at the time of first imaging diagnosis of ICH
- Radiological text report of the brain imaging study that first diagnosed the ICH is available
- Consent obtained from the participant (or their representative if the participant lacks mental capacity)
Who cannot take part
- Previously enrolled in ASPIRING
- Oral antiplatelet or oral anticoagulant drug, or aspirin over the counter, were taken within 24 hours before randomisation
- Investigator believes that prescription of a daily oral antiplatelet drug is required at the time of randomisation
- Antiplatelet drug use is contraindicated
- ICH (intracerebral haemorrhage) exclusively caused by head injury
- ICH secondary to aneurysm, angiitis, arteriovenous malformation/fistula, cavernous malformation, coagulopathy, intracranial venous thrombosis, moyamoya disease, or tumour
- Pregnant, breast-feeding, or of child-bearing potential and not using highly effective contraception
- Enrolled in a study that precludes co-enrolment with ASPIRING
- ICH due to hemorrhagic transformation of cerebral infarction
- Systolic blood pressure (BP) ≥160mmHg at randomisation
- Death appears imminent
- Follow-up will not be possible for the primary and secondary outcomes
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
ASPIRING will test the hypothesis that starting oral antiplatelet drug monotherapy is superior to avoiding antiplatelet drugs, in addition to standard care at the participating hospital, for increasing the time to first major adverse cardiovascular or cerebrovascular events (MACE) for survivors of stroke due to intracerebral haemorrhage (ICH).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe - SM
- Record updated
- 7 May 2026